Investment bank Piper Sandler announced the official initiation of coverage on biopharmaceutical company Definium Therapeutics Inc, assigning it an "Overweight" rating.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Upside bias toward 1.1250 against US Dollar – UOB
Australian Dollar regains ground as Democrats eye victory in both Houses
AI infrastructure demand surges, Arista’s revenue growth sets ten-year record since listing, shares soar 10% after hours
Arista Networks has delivered its most impressive quarterly report since its IPO ten years ago: third-quarter revenue surged 58.5% year-on-year to $3.66 billion, marking the fastest annual growth since its IPO in 2014. This signifies that AI-driven demand for network infrastructure has entered an accelerated release phase. Additionally, fourth-quarter guidance is set at a midpoint of $3.95 billion, surpassing analysts’ previous expectations of $3.6 billion.
Bank Woori Saudara Announces Extraordinary Shareholders Meeting
Crypto prices
More
